Lund, Sweden, 26 April 2019 – The Board of Xintela AB (publ) announces that Peter Edman has been nominated for election to the Board at the annual general meeting on the 27th of May 2019. Greg Batcheller, Karin Wingstrand and Sven Kili have been proposed for re-election. The proposal is supported by major shareholders of the company. It is also announced that board member Claes Post has decided not to stand for re-election.
Peter Edman (born 1954) has over 30 years of experience in drug development in leading positions from Orexo, Sobi, Biovitrum, AstraZeneca, Astra and Pharmacia. Peter has also worked at the Medical Products Agency and been a Professor at the Faculty of Pharmacy, Uppsala University. Peter Edman is currently working as an advisor and board member to companies in the Life Science sector. For the past two years, Peter has been a strategic advisor to Xintela and his election to the board will represent a deepening of his engagement with the company.
“Electing Peter Edman as a member of the Board will broaden Xintela ́s expertise in development and commercialization in this stage of strong growth. His knowledge, experience and network of contacts are of great value to the company’s further development towards clinical studies and commersialization”, says Xintela's Chairman of the Board Gregory Batcheller.
The Board would also like to thank Claes Post for his strong engagement and valuable contribution as a member of the Board since 2013 and wishes him every success with his ongoing and future assignments.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy [at] xintela.se
223 81 Lund